SCHEMBL823757

SCHEMBL823757

CC(=O)Oc1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
KDM4E B2RXH2 4/20 0.50
CYP3A4 P08684 2/20 0.50
ACHE P22303 2/20 0.49
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 2/20 0.47
PKM P14618 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
GLA P06280 2/20 0.46
GAA P10253 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.46
TTR P02766 1/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31621879 1.00 LMNA (0.52) LMNAKDM4ECYP3A4ACHECYP4F2
SCHEMBL16748115 0.87 BACE1 (0.43) LMNAKDM4ECYP3A4ACHEGLA
SCHEMBL18272392 0.85 CES2 (0.45) KDM4ECYP4F2CYP4A11MAPTMAOA
SCHEMBL20296853 0.85 HSD17B10 (0.56) LMNAKDM4ECYP3A4CYP4F2CYP4A11
SCHEMBL24436689 0.84 CYP3A4 (0.56) LMNAKDM4ECYP3A4ACHECYP4F2
SCHEMBL9508276 0.84 MAOB (0.44) LMNAKDM4ECYP3A4ACHECYP4F2
SCHEMBL9929012 0.84 ACHE (0.54) LMNAKDM4ECYP3A4ACHECYP4F2
SCHEMBL1432110 0.84 ACHE (0.59) LMNAKDM4ECYP3A4ACHEMAPT
SCHEMBL377567 0.84 CYP3A4 (0.52) LMNAKDM4ECYP3A4ACHECYP4F2
SCHEMBL16850583 0.84 LMNA (0.44) LMNAKDM4ECYP3A4CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
CN-109535080-A A kind of synthetic method of benzimidizole derivatives 广东省石油与精细化工研究院 2019-03-29 CN claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 US claimed
CN-103483266-B The synthetic method of 2-substituted benzimidazole compounds GUANGDONG TONESET SCIENCE & TECHNOLOGY CO., LTD. (CN) 2016-03-30 CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
CN-103483266-A Synthesis method of 2-substituted benzimidazole compound GUANGDONG TONESET SCIENCE & TECHNOLOGY CO LTD 2014-01-01 CN claimed
CN-103102258-A Compound 4,5-difluoro-2- hydroxyl -1-phenyl butanone, preparation method and agricultural biological activity UNIV QINGDAO AGRICULTURAL 2013-05-15 CN claimed
CN-102153514-A Method for preparing fluorine-containing benzyl benzimidazole compound GUANGDONG TONESET SCIENCE & TECHNOLOGY CO LTD 2011-08-17 CN claimed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
WO-2025125811-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Ontrack Therapeutics Limited (GB) 2025-06-19 WO disclosed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
US-5698584-A NON-STEROIDAL ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA, INC. (CA) 1997-12-16 US disclosed
WO-1997028121-A1 ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-08-07 WO disclosed
CN-1151735-A Benzocycloalkylazolethione derivatives SYNTEX INC (US) 1997-06-11 CN disclosed
WO-1997016435-A1 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-05-09 WO disclosed
WO-1997014691-A1 (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-04-24 WO disclosed
CN-1059142-A New thiophene derivant FUJISAWA PHARMACEUTICAL CO (JP) 1992-03-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS LMNA 3394/4885KDM4E 1964/4885CYP3A4 3084/4885
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS LMNA 3267/4885KDM4E 4414/4885CYP3A4 1025/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS LMNA 3394/4885KDM4E 1964/4885CYP3A4 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.